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The osmotic agents used in peritoneal dialysis solu- major factors: first, the influence of the polymer size on
tions are not metabolically inert and systemic absorption absorption rates (and consequently systemic carbohy-
of these agents results in metabolic alterations that may drate load), and second, the temporal delay introduced
have clinically meaningful consequences [1–4]. The use by the metabolic steps necessary for the breakdown of
of glucose, the most common osmotic agent in peritoneal the carbohydrate polymers to glucose. As addressed else-
dialysis solutions, has been associated with a variety of where in this Supplement issue, icodextrin absorption
metabolic consequences ranging from acute hyperglyce- from the peritoneal cavity occurs predominantly via con-
mia and hyperinsulinemia to dyslipidemia and weight vective pathways (such as, lymphatics) and hence is lim-
gain. Replacement of glucose by glucose polymers [5–11] ited despite the prolonged dwell time. As important, how-
and non-carbohydrate-based osmotic agents (such as ever, is the temporal profile of metabolism of the icodextrin
amino-acids) [2, 12–18] is expected to result in metabolic polymers to glucose. Very little metabolism of icodextrin
profiles distinct from those observed with glucose either polymers occurs in the peritoneal cavity in humans, and
because of the avoidance of the glucose-dependent ef- this metabolism tends to be limited to a reduction in
fects or because of aspects peculiar to these novel os- the concentration of larger polymers with resultant rise
motic agents. In the case of icodextrin both of these in the concentrations of smaller polymers; however, little
attributes apply, and it is the intent of this article to if any glucose is released intraperitoneally. Therefore,
review the metabolic changes and contrast them with from the standpoint of the peritoneal membrane and its
what is observed with dextrose. component cells, icodextrin is functionally a “non-glu-
In addition, we present a review of laboratory changes cose” osmotic agent [1]. After absorption into the sys-
associated with icodextrin use. These include laboratory temic circulation, icodextrin polymers are metabolized
changes thought to be associated with systemic levels of to smaller oligosaccharides by the action of plasma amy-
icodextrin or its metabolites (for example, the decline in lases. The predominant circulating metabolites of ico-
serum sodium and chloride, increase in serum osmolality, dextrin are maltose (2 glucose molecules), maltotriose
etc.), analytical assay interference (such as, icodextrin (3 glucose molecules), and maltotetraose (4 glucose mol-
interference with certain glucose assays and amylase ac- ecules), with little glucose released in the systemic circu-
tivity assays), as well as the compatibility of icodextrin lation due to the absence of circulating maltase. The
with certain drugs commonly used in peritoneal dialysis, release of glucose from the metabolized polymers occurs
such as intraperitoneal insulin and antibiotics. predominantly during the intracellular metabolism of
maltose or other polymers by way of cellular enzymes
involved in carbohydrate metabolism. From this, it is clearMETABOLIC EFFECTS OF ICODEXTRIN
that the “glucose load” arising from the use of icodextrin
It is important at the outset to discuss why the meta-
is “functionally invisible” to the peritoneal cavity and
bolic effects of a glucose polymer can be distinct from
systemic circulation, and its predominant systemic expo-
those of glucose itself. From an overall perspective, the
sure is intracellular. This metabolic profile of icodextrinnet result of the use of a glucose polymer should be the
provides the framework for the following discussion ofsame as for glucose, as a glucose polymer is metabolized
the metabolic effects of icodextrin.ultimately to glucose. However, this is modulated by two
Icodextrin and glycemic profile
The contrasting availability of glucose to the systemicKey words: dialysis solutions, renal replacement therapy, CAPD, APD,
glucose polymer, osmotic agents, dextrose, glycemic profile. circulation between glucose-based solutions and icodex-
trin-based solutions results in a significant difference in 2002 by the International Society of Nephrology
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load and higher insulin levels were noted during the last
three hours for intraperitoneal dosing compared with
oral administration.
In contrast to the acute hyperglycemia and hyperinsu-
linemia associated with glucose-based solutions, icodex-
trin does not lead to hyperglycemia or hyperinsulinemia
following its intraperitoneal administration. As discussed
earlier in this article, little or no free glucose is liberated
within the peritoneal cavity following administration of
icodextrin and, further, the metabolism of the carbo-
hydrate polymers to glucose has a latency period caused
by multiple metabolic steps: extracellular metabolism
of large carbohydrate moieties to oligosaccharides withFig. 1. Absorption of glucose during a long dwell (8 h) is dependent on
the peritoneal transport profile determined by a peritoneal equilibration smaller degrees of polymerization (maltose, maltotriose,
test. The expected amounts of glucose absorbed at various tonicities etc.); uptake of small oligosaccharides into cells; and fi-of dialysis solution dextrose derived from validated computer modeling
nally release of glucose within cells by intracellular mal-(PD Adequest, Baxter Healthcare Corporation, Deerfield, IL, USA
[59, 60]) are shown. Symbols are: ( ) 1.50%; () 2.50%; () 4.25%. tases. During the transit of icodextrin from the peritoneal
cavity to its site of final intracellular metabolism, very
little glucose is produced in the extracellular compart-
ment. This assertion is supported by the observation de-
the acute glycemic effects of the two solutions. Following
scribed in the kinetics paper in this supplement whereby
intraperitoneal instillation of glucose-based solutions, glu-
the peritoneal instillation of icodextrin did not result in
cose is rapidly absorbed by diffusion across paracellular any measurable alterations in plasma glucose or plasma
pathways and appears immediately in the circulation. insulin (Fig. 3).
The concentrations of glucose in the dialysis solution The absence of hyperglycemia and hyperinsulinemia
(ranging from 1360 mg/dL to 3860 mg/dL) far exceed cir- with icodextrin may have an influence on the manage-
culating concentrations of glucose even in poorly con- ment of patients with diabetes [20]. In diabetic PD pa-
trolled diabetic patients and the transport is predomi- tients requiring insulin administration, the hyperglycemic
nantly unidirectional from the peritoneal cavity to the response to glucose-based solutions is managed clinically
circulation. This influx of glucose is also dependent on by either addition of insulin to the dialysis solution or
the transport characteristics of the patient’s peritoneal by adjustments in peripheral insulin dose to compensate
membrane (Fig. 1). for the hyperglycemic response. Initiation of treatment
Delarue et al evaluated the metabolic impact of intra- with icodextrin in these patients may require modification
peritoneal (IP) glucose relative to an equivalent oral of their insulin dose. In addition, since hyperglycemia
dose in nine patients undergoing continuous ambulatory adversely affects ultrafiltration in diabetic patients un-
peritoneal dialysis (CAPD; Fig. 2) [3, 19]. Their study dergoing PD [21], the absence of fluctuations in blood
measured blood glucose and insulin levels during a six- glucose levels during icodextrin use may help to improve
hour dwell with 4.25% dextrose. Both intraperitoneal ultrafiltration in patients with poor glycemic control.
and oral glucose were associated with an acute glycemic The studies described previously have contrasted the
response (Fig. 2). During intraperitoneal administration, acute effects of glucose-based and icodextrin-based dial-
blood glucose levels increased from 5.1  0.3 mmol/L ysis solutions on insulin levels. Evaluations during chronic
to a peak level of 9.2  0.6 mmol/L at one hour. While clinical use have also been performed. In a study by
the increase in blood glucose was similar after oral and Amici et al, the impact of icodextrin-based dialysis solu-
intraperitoneal administration, the resolution of the hy- tion on serum insulin and insulin sensitivity was evalu-
perglycemic response was delayed after intraperitoneal ated [22]. Insulin sensitivity was measured in 27 non-
administration compared to oral glucose administration. diabetic CAPD patients using the Homeostasis Model
The fate of the absorbed glucose (oxidation) was found Index (HOMA), which is a validated and widely used
to be similar for both routes of administration. instrument [23–29]. Twelve patients were treated with
As expected, the hyperglycemic response to intraperi- standard glucose solutions during the daytime and ico-
toneal glucose administration was also associated with an dextrin for the nighttime dwell; 15 patients received stan-
acute hyperinsulinemic response. Insulin levels increased dard glucose for all exchanges. Median duration of study
from 76  9 pmol/L to a peak of 308  82 pmol/L at treatment was nine months. The icodextrin group showed
two hours and decreased to near baseline by four hours. significantly lower serum insulin levels (28.6  6.0 vs.
The peak insulinemic effect of intraperitoneal glucose 36.1  10.2 for glucose controls, P  0.02) and greater
insulin sensitivity with significantly higher HOMA indexwas observed later than the response after oral glucose
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Fig. 2. Hyperglycemic and hyperinsulinemic
response to oral glucose () and intraperito-
neal 4.25% dextrose dialysis solution () [19].
Table 1. Approximate caloric contribution of icodextrin
compared to dextrose-based PD solutions
Icodextrin 2.5% dextrose 4.25% dextrose
150 gramsa 45.4 gramsb 77.2 gramsc
% Absorbed/8-hour dwell 25%d 86% 86%
Approx. g of CHO
absorbed/dwell 37.5 39 66
Approximate Kcal/dwell 150 156 266
a Total amount administered in 2 L of 7.5% icodextrin
b Total amount administered in 2 L of 2.5% dextrose (2.27% anhydrous glu-
cose)
c Total amount administered in 2 L of 4.25% dextrose (3.86% anhydrous
glucose)
d From Mistry, Gokal et al. 1994 [5, 8]
the substantially slower absorption of icodextrin from
the dialysate results in a lower calorie load. Although the
precise caloric load due to icodextrin has not been deter-
mined, the maximum carbohydrate load may be esti-
Fig. 3. Lack of effect of icodextrin on glucose or insulin levels during mated by the total amount of glucose polymer absorbed
a long dwell.
from the peritoneal cavity. It should be pointed out,
however, that this value typically overestimates the calo-
ric load because a portion of the administered icodextrin
and its metabolites is eliminated from blood by dialysisvalues (2.7  0.5 vs. 2.2  0.7 for glucose controls, P 
and renal clearance (in patients with residual renal func-0.04). Icodextrin treatment also was associated with a
tion), as well as by removal of residual icodextrin fromlower carbohydrate load, though the difference did not
the peritoneal cavity during subsequent exchanges.reach statistical significance (128 31 vs. 142 43 g/day
In the Multicenter Investigation of Icodextrin in Am-for glucose controls). The two groups were similar with
bulatory Peritoneal Dialysis (MIDAS) [8], a randomizedrespect to fasting glucose, and body mass index [22].
These preliminary findings suggest a clinical benefit for controlled trial of 209 patients on CAPD, carbohydrate
icodextrin in reducing serum insulin and enhancing insu- absorption during 8-hour overnight dwells was signifi-
lin sensitivity when used for the long nighttime dwell cantly lower (P  0.01) with icodextrin (29 g) than with
during CAPD. 4.25% dextrose (62 g). The percent absorption of initially
infused carbohydrate was 20% with icodextrin and 86%
Icodextrin and carbohydrate load with 4.25% dextrose, corresponding to difference of more
than 100 kcal/dwell in the estimated caloric load betweenThe substantial glucose absorption (150 to 300 g per
day) associated with use of standard glucose-based dial- the two solutions (Table 1).
The reduced ultrafiltration efficiency of glucose-basedysis solutions imposes a carbohydrate load that can lead
to longer-term metabolic complications such as obesity solutions during long dwells also may increase the re-
quirement for higher glucose concentrations and/or addi-and dyslipidemia [12, 30, 31]. In contrast to glucose,
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tional short exchanges to achieve adequate ultrafiltration abnormalities in plasma lipoproteins are reported in PD
patients, including a significant increase in apolipopro-and hence further increased glucose load. For example,
in patients on automated peritoneal dialysis (APD), the tein B [37]. These changes in lipoprotein composition can
be observed in the absence of overt changes in the plasmalong daytime dwell is frequently characterized by a low
drain volume and negative net ultrafiltration when glu- lipid profile [38]. Although the metabolic consequences
of increased glucose load are generally considered to leadcose-based solutions are used, and it has been reported
that over 80% of patients on APD have a negative net to an elevation of plasma triglycerides [30], both hyper-
glycemia and hyperinsulinemia also may increase pro-UF during the daytime dwell with 2.5% dextrose solu-
tion [32; see Note Added In Proof]. In clinical practice, duction of apolipoprotein B containing lipoproteins and
influence lipoprotein composition and density [39]. Thenighttime ultrafiltration in these patients needs to be
enhanced by use of higher glucose concentrations to evidence of overproduction of apolipoprotein B-con-
taining lipoproteins [37, 40] and accumulation of small,compensate for the therapeutic failure of the daytime
dwell. The use of icodextrin for the long daytime dwell dense LDL [41] in PD patients supports the hypothesis
of a direct causal relationship between glucose load andin APD corrects the therapeutic failure and the need for
enhanced nocturnal ultrafiltration may be attenuated. dyslipidemia in PD, even though a direct correlation has
not been readily demonstrated [36].This concept has been confirmed by the work of Bajo
et al [abstract; Perit Dial Int 19(Suppl 1):S49, 1999]. In Several studies suggest that icodextrin is associated
with a more favorable lipid and lipoprotein profile com-an eight-week crossover study to compare the effects of
icodextrin and dextrose for the daytime exchange in 17 pared with standard glucose solutions (abstract; Gokal
et al, J Am Soc Nephrol 9:283, 1998) [42]. In a secondarypatients on APD, the increase in ultrafiltration (UF)
rate with icodextrin was accompanied by a significant analysis of fasting lipids from the randomized open-label
MIDAS study comparing an overnight exchange withdecrease in nightly glucose load (289 to 266 g; P 0.05).
A recently completed randomized, controlled trial also 7.5% icodextrin with standard glucose, total and LDL
cholesterol decreased significantly after six months treat-suggests that the lower caloric load associated with ico-
dextrin contributes to a reduction in weight gain com- ment with icodextrin (abstract; Gokal, ibid). This effect
was particularly pronounced in patients with baselinepared with glucose-based solutions (abstract; Wolfson et
al, J Am Soc Nephrol 12:317A, 2001). In a 52-week, hyperlipidemia (TC 6.5 mmol/L; Table 2). Although
significant reductions in total cholesterol (TC) were ob-double-blind trial of icodextrin versus 2.5% dextrose,
the change in body weight (evaluated before drain) was served with both solution types (P  0.01 and P  0.05
vs. baseline) at the end of six months, only patients insignificantly less in patients treated with icodextrin than
dextrose (abstract; Wolfson, ibid). At week 52, patients the icodextrin group experienced significant reductions
in LDL cholesterol. Following six months of treatment,receiving 2.5% dextrose had gained an average of 2.33
kg in body weight, while the icodextrin-treated patients hyperlipidemic patients on icodextrin experienced a 16%
reduction in LDL cholesterol on average, which waslost an average of 0.03 kg in body weight. Although body
composition was not investigated in this study, it is likely significantly different from changes noted among glucose
controls (P  0.038). No significant changes in very lowthat the differences in weight gain represent differences
in the amount of body fat due to the reduced glucose density lipoprotein (VLDL) or high density lipoprotein
(HDL) cholesterol, plasma triglycerides, or lipopro-load [31]. Even greater differences in weight might be
expected when comparing patients on icodextrin to pa- tein(a) [Lp(a)] were observed (abstract; Gokal, ibid).
In another study, Bredie et al evaluated the impact oftients using 4.25% dextrose for the overnight dwell. In
summary, the slower absorption of icodextrin, leading 7.5% icodextrin on lipid metabolism in a randomized
crossover study involving 21 non-diabetic patients onto a reduced carbohydrate load, along with its improved
efficiency at sustaining ultrafiltration during long dwells, CAPD [42]. Participants were randomly assigned to re-
ceive an overnight dwell with either standard glucoseall may help to reduce the caloric load and minimize
weight gain in PD patients. solution (1.5%, 2.5%, or 4.25% dextrose) or a 7.5%
icodextrin-containing solution for six weeks. After six
Icodextrin and lipid profile weeks of treatment with icodextrin, there were signifi-
cant reductions from baseline in total cholesterol (5.43The continuous absorption of glucose is considered to
lead or contribute to dyslipidemia in PD patients [30, 0.85 to 4.86 0.70 mmol/L,11%; P 0.001) and LDL
cholesterol (3.38  0.87 to 2.93  0.73 mmol/L, 13%;33, 34], although a direct association between glucose
load and lipid levels has not been demonstrated [35, 36]. P 0.001). Plasma free fatty acids and triglyceride levels
also tended to decrease (from 0.16  0.10 to 0.13  0.08Patients treated by peritoneal dialysis generally have
higher plasma total cholesterol, low density lipoprotein mmol/L, P  0.06, and from 2.14  1.96 to 1.92  1.03
mmol/L, respectively). While HDL cholesterol was also(LDL) cholesterol and triglycerides than uremic patients
or their hemodialysis counterparts [33, 34]. In addition, reduced following icodextrin therapy (from 0.95  0.27
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Table 2. Changes in total cholesterol and LDL-cholesterol with icodextrin and dextrose treatment
Icodextrin Dextrose
N Baseline 6 Months N Baseline 6 Months
All patients
Total cholesterol 65 6.90.2 6.50.2a 68 6.80.2 6.60.2
LDL-cholesterol 23 5.10.4 4.50.3b 23 4.50.3 4.30.4
Hypercholesterolemic patients
Total cholesterol 29 8.60.3 7.60.3b 39 8.00.2 7.60.2a
LDL-cholesterol 12 6.20.4 5.20.5b 12 5.60.3 5.50.4
Values are expressed in mmol/L (mean  SEM); from Gokal et al (abstract; J Am Soc Nephrol 9:283, 1998).
a P  .05 vs. baseline; b P  .01 vs. baseline
to 0.90  0.24 mmol/L, P  0.029), the plasma TC:HDL
ratio remained constant. These findings suggest a bene-
ficial effect of icodextrin on the lipid profile of patients
on CAPD when used for the long overnight dwell ex-
change in place of glucose.
These improvements in lipid profiles, along with the
reduction in weight gain and improved insulin sensitivity
suggest that the reduced caloric load (or temporary re-
prieve from glucose-based dialysis solutions during the
long dwell) may hold the potential for reducing cardio-
vascular risk in PD patients using icodextrin. Further
controlled clinical study is needed to evaluate these met-
abolic benefits or to establish a difference in clinical Fig. 4. A small decline in plasma sodium is observed during long-term
administration of icodextrin. Data represent pooled results from severaloutcome for patients using icodextrin.
controlled trials in which the control was 2.5% dextrose (Data on file,
Baxter Healthcare Corporation). Symbols are: () icodextrin; () 2.5%
dextrose; *P  0.001 vs. 2.5% dextrose.LABORATORY EFFECTS OF ICODEXTRIN
The systemic absorption of icodextrin and its metabo-
lism to maltose and other oligosaccharides result in sev-
eral laboratory changes as well as interference in certain trolled clinical trials [8, 43, 44]. In trials comparing ico-
laboratory assays. A modest decline in serum sodium dextrin and 2.5% dextrose, mean values for serum so-
and chloride is known to occur in response to treatment dium were within normal limits (normal range 135 to
with icodextrin and slight increases in serum (or plasma) 148 mmol/L; 135 to 148 mEq/L) in both treatment groups
osmolality and alkaline phosphatase have been reported at each evaluation point, but were consistently near the
in some studies (see below). These changes are likely lower limit of normal in the icodextrin group. Changes
related to the presence in plasma of osmotically active, in serum sodium associated with icodextrin therapy rela-
small oligosaccharide metabolites of icodextrin or possi- tive to 2.5% dextrose across all trials are presented in
bly larger carbohydrate polymers in the case of alkaline Figure 4. Serum sodium levels decreased early after the
phosphatase. The presence in plasma of icodextrin and
initiation of icodextrin, were stable over time, and rap-its metabolites also results in interference in certain labo-
idly returned to baseline values after discontinuation ofratory assays, such as serum glucose when measured
treatment [45]. The greatest mean change from baselineusing commercial kits containing glucose dehydrogenase
with icodextrin was 3.6 mmol/L. Serum chloride typi-of the pyrroloquinolinequinone (GDH PQQ) class and
cally followed a similar pattern.serum amylase activity when measured by certain assay
The decline in serum sodium and chloride associatedkits. These laboratory changes and assay interference,
with icodextrin therapy is caused mainly by a dilutionalparticularly the interference in glucose determination,
effect resulting from blood levels of icodextrin metabo-may have important implications in the management
lites, particularly maltose and maltotriose. The presenceof patients treated with icodextrin. For that reason, we
of osmotically active particles in the vascular compart-review these laboratory changes along with their pro-
ment is sufficient to cause a slight shift in water from theposed mechanisms and possible clinical implications.
interstitial and cellular compartments to the vascular com-
Sodium and chloride partment, resulting in the dilutional hyponatremia (some-
times called hypertonic hyponatremia). This dilutionalDecreases in serum sodium and chloride have been
observed in multiple studies of icodextrin, including con- hyponatremic effect is similar to that due to hyperglyce-
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Fig. 5. The acute decline in plasma sodium during a first single dwell
with icodextrin parallels the increase in plasma icodextrin levels. Sym-
bols are: () sodium; () icodextrin.
Fig. 6. Changes in alkaline phosphatase during long-term administra-
tion of icodextrin. Symbols are: () icodextrin; () 2.5% dextrose.
mia [46–49] or the presence of mannitol-like solutes in
blood [50]. Hyponatremia due to maltose infusion also has been reported in other studies [8]. The increase in
has been reported in a patient with renal impairment mean plasma osmolality observed at one month (1.40
[51]. This proposed mechanism is supported by the close mOsm/kg compared to patients using 2.5% dextrose)
temporal relationship between plasma levels of icodex- did not appear to persist throughout the study. Similar
trin and the decline in serum sodium observed during to the observations for sodium and chloride, the modest
the single, 12-hour exchange with icodextrin in the phar- increase in plasma osmolality is likely related to the
macokinetic study reported elsewhere in this supplement increase in low molecular weight icodextrin metabolites,
(Fig. 5).
particularly maltose and maltotriose, as molar concentra-
The decline in serum sodium and chloride is generally
tions of these metabolites yield the greatest values. Themodest and rarely results in adverse event reports of
clinical significance of these findings is expected to behyponatremia. However, Gradden et al have recently
minimal, as the changes due to icodextrin are small andreported neurological complications secondary to hypo-
in large part transitory due to the dilutional effects ofnatremia in two diabetic patients using icodextrin [43].
icodextrin discussed above.Both of these patients presented with hyperglycemia (glu-
cose 50 mmol/L; 900 mg/dL), hyponatremia (sodium Alkaline phosphatase
121 mmol/L; 121 mEq/L) and neurological problems,
A small increase in mean serum alkaline phosphatasespecifically seizures in one patient and markedly de-
(ALP) has been reported in some studies of icodextrinpressed consciousness level in the other. Following these
(abstract; Wolfson, ibid) [45]. In combined comparativeevents, the authors examined sodium levels in their en-
studies of icodextrin versus 2.5% dextrose, mean ALPtire group of patients on peritoneal dialysis (PD). Sodium
levels increased significantly (mean increase 17.3 U/L),levels prior to initiation of icodextrin were significantly
but remained within normal limits at all time-points andlower in diabetic patients than in non-diabetic patients
did not show evidence of a progressive increase over a(P 0.005), although the absolute level remained within
12-month study period (Fig. 6). ALP levels returned tothe normal range in both groups (136 to 145 mmol/L).
baseline coincident with the return of icodextrin andSodium levels after initiation of icodextrin were signifi-
metabolite blood levels to pretreatment values, sug-cantly lower than pre-icodextrin levels in both diabetic
gesting that elevations were neither permanent nor re-(P  0.05) and non-diabetic patients (P  0.05), but fell
lated to significant alterations in liver function.below the lower limit of the normal range only in diabetic
Bone, liver and intestinal ALP isoforms were mea-patients, suggesting that the effects of hyperglycemia and
sured in a subset of patients participating in a four-weekicodextrin are additive. Therefore, use of icodextrin may
safety and efficacy evaluation of icodextrin versus 2.5%produce clinically relevant symptoms if, as in their two
dextrose for the long overnight dwell in CAPD (abstract;cases, the hyponatremia is compounded by other factors,
Mongoven et al, Perit Dial Int 22:118, 2002. As shownsuch as poor blood sugar control.
in Figure 7, the increase in total ALP (from 100  10
Plasma osmolality to 115  12 U/L; 15%), was accounted for by a small
rise in each of the three ALP isoforms: bone isoformUse of icodextrin has been associated with a slight
from 56 9 to 62 11 (11%), liver isoform from 41increase in plasma osmolality in some studies [44], al-
though this effect is variable and no significant change 3 to 46  3 (12%), and intestinal isoform from 3  1
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ysis (CAPD) using icodextrin [54, 55]. Maltose inter-
feres with glucose assays that utilize glucose dehydroge-
nase enzymes of the pyrroloquinolinequinone class (GDH
PQQ), causing falsely elevated readings. The overesti-
mation of glycemia is likely due to the presence of malt-
ose and other oligosaccharide metabolites of icodextrin
in the systemic circulation and the reaction of GDH-
PQQ with the free reducing group of the glucose mole-
cule located at the end of each saccharide chain.
Wens et al evaluated the magnitude and conditions
surrounding these discrepancies in CAPD patients on
icodextrin for at least one week (chronic use group) and
CAPD patients after exposure to a single exchange of
icodextrin (acute use group) [55]. In six CAPD patients
treated with once-daily exchanges with icodextrin for aFig. 7. Changes in alkaline phosphatase isoenzymes during icodextrin
administration. Symbols are: ( ) liver; () bone; () intestinal. minimum of seven consecutive days, the overestimation
of glycemia by the GDH PQQ-based methods was 65 
26 mg/dL compared to reference values (P  0.01). In
six CAPD patients studied at the end of one single ico-
to 7 1 (119%; all P 0.01 vs. baseline). On a propor- dextrin exchange, overestimation of 61  11 mg/dL was
tional basis, however, the percentage increase in intesti- observed (P  0.001). Spiking of whole blood from a
nal ALP appeared greater than for the bone or liver normal subject with concentrated solutions of glucose
isoforms. Although this may be related to the fact that and icodextrin and some of its metabolites (maltose,
the intestinal isoform represents a smaller proportion of maltotriose, maltopentaose) similarly resulted in overes-
total ALP, it is possible that the intestinal ALP isoforms timates with the GDH PQQ-based methods. The overes-
may be affected differently by icodextrin. timation decreased as the molecular size of the saccha-
One proposed mechanism for the small increase in rides added to blood increased. The wide variability in
ALP during icodextrin treatment is a partial inhibition the overestimated difference among patients precludes
of ALP clearance due to competition between ALP and the derivation of a “correction factor” to be used in ad-
icodextrin for hepatocyte asialoglycoprotein receptors. justments when GDH PQQ-based methods are used.
Clearance of ALP is mediated by the presence of carbo- Glucose monitoring systems that utilize GDH PQQ-
hydrate on the protein, and interference of ALP clearance based methods are thus not suitable for regular monitor-
has been reported due to other carbohydrates [52, 53]. ing of glycemia in diabetic peritoneal dialysis patients
Differences in the carbohydrate composition of the intes- treated with icodextrin. To prevent maltose interference
tinal isoform, which is much more heavily asialoglycated, with test results, systems that utilize a glucose-specific
may account for the greater impact on clearance of this method should be used, such as glucose oxidase, hexoki-
isoform. Further investigation is needed to confirm this nase, or classes of glucose dehydrogenases other than
proposed mechanism and to evaluate whether clearance GDH PQQ. Since manufacturers of glucose monitors
other asialoglycoproteins may be delayed due to icodex- may change assay methods, it is not possible in this article
trin. to provide a comprehensive list of the products that
Increases in ALP were not associated with any clinical utilize GDH PQQ. We suggest that clinicians refer to
symptoms, adverse events or abnormalities in any other the product labeling included in test strip packages or
liver function tests. Since ALP values rapidly return to contact the glucose monitor manufacturers.
baseline upon discontinuation of icodextrin treatment
Icodextrin interference in serum amylase assaysand other liver enzymes are unaffected, other mecha-
nisms such as bile duct obstruction are unlikely. Also, An apparent decrease in serum amylase activity has
the lack of a rise in any one particular isoform indicates been reported in multiple studies of icodextrin [45, 56,
that the minor increase in serum ALP is unlikely to be 57]. Levels of serum amylase activity declined 70 to 90%
related to specific organ toxicity. within one week of icodextrin administration and re-
mained low (but stable) during administration. Upon dis-
Icodextrin interference in enzymatic glucose assays continuation of icodextrin administration, serum amylase
Discrepancies between serum glucose measurements activity returned to baseline levels (Fig. 8) [45]. In com-
obtained with select glucose analyzers and those ob- bined data from comparative trials, icodextrin treatment
tained using reference methods have been noted in dia- was associated with consistently lower plasma amylase
levels compared with 2.5% dextrose and the differencebetic patients on continuous ambulatory peritoneal dial-
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Table 3. Results of drug compatibility studies with icodextrin
Percent of
Initial Activity
Drug Other Drugs Present Dose (48 hr at 25C)
Gentamicin Vancomycin  insulin 4 mg/L 101
68 mg/L 101
Vancomycin Heparin  insulin 20 mg/L 96
909 mg/L 99
Insulin Heparin  gentamicin  2 U/L 91
vancomycin
57 U/L 76
Heparin Vancomycin  insulin 1250 U/L 98
2270 U/L 103
Cefazolin None 250 mg/L 93
750 mg/L 93
Ceftazidime None 125 mg/L 92
500 mg/L 90
Netlimycin None 4 mg/L 113
Fig. 8. Changes in plasma amylase during icodextrin administration. 60 mg/L 107
Symbols are: () icodextrin; () 2.5% dextrose.
Data are from Choo et al [abstract; Perit Dial Int 17(Suppl):S94, 1997].
Table 4. Metabolic and laboratory effects of icodextrin
between treatment groups was statistically significant at
Dextrose Icodextrineach study visit (P  0.001).
Metabolic effectsIn vitro studies indicate that icodextrin and its metabo-
Glucose absorption Yes Nolites interfere directly with the enzymatic-based amylase
Hyperglycemia Yes No
assay, resulting in inaccurately low values (abstracts; Hyperinsulinemia Yes No
Increased insulin sensitivity No YesSchoenicke, J Am Soc Nephrol, 10:229A, 1999; Schoenicke,
Hyperlipidemia Yes NoPerit Dial Int, 21(Suppl 1):S31, 2001). Routine clinical
Weight gain Yes No
methods for amylase activity employ a dye-labeled oligo- Laboratory effects
Dilutional hyponatremia No Yessaccharide as an amylase substrate, which is interfered
Increased plasma osmolality No Slightwith competitively by the presence of icodextrin (ab- Increased alkaline phosphatase No Slight
stract; Wang et al, Perit Dial Int 22(Suppl 1):S17, 2002). Apparent decrease in serum amylase activity No Yes
Interference in enzymatic glucose assays No YesTherefore, icodextrin interferes with amylase activity
Interference with creatinine analysis Yes Nomeasurements by acting as a competitive inhibitor in the
amylase activity assay and an increase in the substrate
concentration in the assay would be expected to reduce
the interference.
tabolites at various concentrations using both the Jaffe`
No adverse clinical effect has been attributed to this
and Creatinine Plus methods. Interference was deter-
decline in measured amylase activity. Although the inter- mined in samples containing 0.6 to 20 mg/dL creatinine
action has not been associated with any clinical adverse in saline solution or in plasma (N  6), and in dialysate
events, this laboratory interference should be taken into samples (N  6) spiked with icodextrin, maltose, malto-
account when attempting to diagnose or monitor pancre- triose, and maltotetraose at concentrations up to twofold
atitis in patients using icodextrin. It is recommended that the level found in plasma and dialysate from patients
serum amylase should not be used in the diagnosis or treated using icodextrin. Results confirm that no interfer-
monitoring of pancreatitis in patients using icodextrin. ence occurs when using either the colorimetric Jaffe
Determination of serum lipase activity does not appear method or the enzymatic Creatinine Plus method at lev-
to be influenced by the presence of icodextrin and there- els up to 65 g/L icodextrin, 2 g/L maltose, 2 g/L malto-
fore may be an adequate method to diagnose pancreatitis triose, and 1 g/L maltotetraose, levels representing worst-
(Schoenicke, Perit Dial Int, ibid). case clinical concentrations.
Creatinine assay
ICODEXTRIN COMPATIBILITY WITH DRUGSGlucose has been reported to interfere in the analysis
ADMINISTERED INTRAPERITONEALLYof creatinine by the Jaffe` method. The potential interfer-
ence of icodextrin and its primary metabolites (maltose, The effect of icodextrin on intraperitoneally adminis-
maltotriose, maltotetraose) on creatinine measurements tered insulin was evaluated in six insulin-dependent dia-
was recently evaluated by Burke et al [58]. They evalu- betic patients undergoing CAPD. Patients were random-
ized in a crossover design to receive icodextrin or 1.5%ated the potential interference of icodextrin and its me-
Gokal et al: Metabolic effects of icodextrinS-70
toneal dialysis in adult and pediatric patients. Perit Dial Int 19dextrose with their usual insulin dose, administered in-
(Suppl):S429–S434, 1999
traperitoneally with the exchange. Insulin absorption 3. Delarue J, Maingourd C: Acute metabolic effects of dialysis
fluids during CAPD. Am J Kidney Dis 37(Suppl):S103–S107, 2001was similar in the two groups (P  0.97), and there
4. Druml W: Metabolic aspects of continuous renal replacementwere no differences in plasma or dialysate insulin levels
therapies. Kidney Int 56(Suppl 72):S56–S61, 1999
between the two groups (P 0.67 and 0.22, respectively). 5. Gokal R, Mistry CD, Peers E: A United Kingdom multicenter
study of icodextrin in continuous ambulatory peritoneal dialysisMean plasma glucose levels were higher during 1.5%
(MIDAS). Perit Dial Int 14(Suppl 2):S22–S27, 1994dextrose treatment, although this result did not reach
6. Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al: Peri-
statistical significance because of the variability and small toneal transport characteristics with glucose polymer based dialy-
sate. Kidney Int 50:979–986, 1996sample size (P  0.10). Therefore, icodextrin does not
7. Krediet RT: Glucose polymer solution (Icodextrin) is ideal forinterfere with insulin absorption from the peritoneal cav-
high peritoneal transporter. Perit Dial Today 4:14–15, 1998
ity or the ability of insulin to control blood glucose, 8. Mistry CD, Gokal R, Peers E: MIDAS Study Group: A ran-
domized multicenter clinical trial comparing isosmolar icodextrinalthough it must be remembered that dextrose-based
with hyperosmolar glucose solutions in CAPD. Kidney Int 46:496–solutions (particularly 4.25%) contribute to hyperglyce-
503, 1994
mia whereas icodextrin does not. 9. Mistry CD, Gokal R: Optimal use of glucose polymer (icodextrin)
in peritoneal dialysis. Perit Dial Int 16(Suppl 1):S104–S108, 1996While no formal clinical drug interaction studies of
10. Peers E, Gokal R: Icodextrin: Overview of clinical experience.icodextrin have been conducted with antibiotics or other
Perit Dial Int 17:22–26, 1997
drugs (for example, heparin), in vitro studies (Table 3) 11. Posthuma N, ter Wee PM, Donker AJM, et al: Assessment of
the effectiveness, safety, and biocompatibility of icodextrin insuggest that addition of these drugs (either indepen-
automated peritoneal dialysis. Perit Dial Int 20(Suppl 2):S106–dently or in combination) to icodextrin-based solution
S113, 2000
does not appear to result in any loss of activity [abstract; 12. Brulez HF, van Guldener C, Donker AJ, ter Wee PM: The
impact of an amino acid-based peritoneal dialysis fluid on plasmaChoo et al, Perit Dial Int 19(Suppl 1):S94, 1997].
total homocysteine levels, lipid profile and body fat mass. Nephrol
Dial Transplant 14:154–159, 1999Summary
13. Canepa A, Carrea A, Menoni S, et al: Acute effects of simultane-
ous intraperitoneal infusion of glucose and amino acids. KidneyAs shown in Table 4 the use of icodextrin based perito-
Int 59:1967–1973, 2001neal dialysis fluid for the long dwell in PD patients is
14. Delarue J, Maingourd C, Objois M, et al: Effects of an amino
associated with metabolic and laboratory effects, which acid dialysate on leucine metabolism in continuous ambulatory
peritoneal dialysis patients. Kidney Int 56:1934–1943, 1999are different than those observed for dextrose-based so-
15. Jones M, Hagen T, Boyle CA, et al: Treatment of malnutritionlutions. Apart from the retention of icodextrin metabo-
with 1.1% amino acid peritoneal dialysis solution: Results of a
lites in plasma, the metabolic effects of icodextrin are in multicenter outpatient study. Am J Kidney Dis 32:761–769, 1998
16. Ueda Y, Miyata T, Goffin E, et al: Effect of dwell time on carbonylgeneral less conspicuous than those of dextrose solutions.
stress using icodextrin and amino acid peritoneal dialysis fluids.Although icodextrin is a polymer of glucose molecules,
Kidney Int 58:2518–2524, 2000
its higher molecular weight, slower absorption from the 17. Werynski A, Waniewski J, Wang T, et al: Kinetic studies of
peritoneal cavity and gradual metabolism by serum amy- dipeptide-based and amino acid-based peritoneal dialysis solutions.
Kidney Int 59:363–371, 2001lase prevent the hyperglycemia, hyperinsulinemia and
18. Wolfson M, Jones M: Intraperitoneal nutrition. Am J Kidney Disother metabolic effects that are associated with hyper- 33:203–204, 1999
tonic dextrose solutions. The temporal profile of the 19. Delarue J, Maingourd C, Lamisse F, et al: Glucose oxidation
after a peritoneal and an oral glucose load in dialyzed patients.peritoneal absorption and metabolism of icodextrin thus
Kidney Int 45:1147–1152, 1994explains why the metabolic effects of this glucose poly- 20. Wong TY, Chan JC, Szeto CC, et al: Clinical and biochemical
mer are distinct from those of glucose itself. characteristics of type 2 diabetic patients on continuous ambulatory
peritoneal dialysis: Relationships with insulin requirement. Am J
Kidney Dis 34:514–520, 1999
21. Mujais S, Nolph K, Gokal R, et al: Evaluation and managementNOTE ADDED IN PROOF
of ultrafiltration problems in peritoneal dialysis. International Soci-
Wolfson M, Picaino B, Hamburger RJ, Morton R ety for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration
Management in Peritoneal Dialysis. Perit Dial Int 20(Suppl 4):S5–for the Icodextrin Study Group: Efficacy and long-term
S21, 2000safety of icodextrin in peritoneal dialysis. Am J Kidney
22. Amici G, Orrasch M, Da Rin G, Bocci C: Hyperinsulinism reduc-
Dis, In press. tion associated with icodextrin treatment in continuous ambulatory
peritoneal dialysis patients. Adv Perit Dial 17:80–83, 2001
Reprint requests to Salim Mujais, M.D., Renal Division, Baxter 23. Arad Y, Newstein D, Cadet F, et al: Association of multiple
Healthcare Corporation, 1620 Waukegan Rd., MPGR-D1, McGaw risk factors and insulin resistance with increased prevalence of
Park, Illinois 60085-9815, USA. asymptomatic coronary artery disease by an electron-beam com-
E-mail: mujaiss@baxter.com puted tomographic study. Arterioscler Thromb Vasc Biol 21:2051–
2058, 2001
24. Shoji T, Emoto M, Nishizawa Y: HOMA index to assess insulinREFERENCES
resistance in renal failure patients. Nephron 89:348–349, 2001
25. Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM: Clini-1. Holmes CJ, Shockley TR: Strategies to reduce glucose expo-
cally useful estimates of insulin sensitivity during pregnancy: Vali-sure in peritoneal dialysis patients. Perit Dial Int 20(Suppl):S37–
dation studies in women with normal glucose tolerance and gesta-S41, 2000
2. Shockley TR, Martis L, Tranaeus AP: New solutions for peri- tional diabetes mellitus. Diabetes Care 24:1602–1607, 2001
Gokal et al: Metabolic effects of icodextrin S-71
26. Ikeda Y, Suehiro T, Nakamura T, et al: Clinical significance of neal dialysis with an overnight icodextrin dwell on parameters of
glucose and lipid metabolism. Perit Dial Int 21:275–281, 2001the insulin resistance index as assessed by homeostasis model as-
sessment. Endocr J 48:81–86, 2001 43. Gradden CW, Ahmad R, Bell GM: Peritoneal dialysis: New
developments and new problems. Diabet Med 18:360–363, 200127. McAuley KA, Williams SM, Mann JI, et al: Diagnosing insulin
resistance in the general population. Diabetes Care 24:460–464, 2001 44. Posthuma N, ter Wee PM, Donker AJM, et al: Serum disaccha-
rides and osmolality in CCPD patients using icodextrin or glucose28. Katsuki A, Sumida Y, Gabazza EC, et al: Homeostasis model
assessment is a reliable indicator of insulin resistance during follow- as daytime dwell. Perit Dial Int 17:602–607, 1997
45. Plum J, Gentile S, Verger C, et al: Efficacy and safety of aup of patients with type 2 diabetes. Diabetes Care 24:362–365, 2001
29. Lansang MC, Williams GH, Carroll JS: Correlation between 7.5% icodextrin peritoneal dialysis solution in patients treated with
automated peritoneal dialysis. Am J Kidney Dis 39:862–871, 2002the glucose clamp technique and the homeostasis model assessment
in hypertension. Am J Hypertens 14:51–53, 2001 46. Katz MA: Hyperglycemia-induced hyponatremia–Calculation of
expected serum sodium depression. N Engl J Med 289:843–844, 197330. Lindholm B, Norbeck HE: Serum lipids and lipoproteins during
continuous ambulatory peritoneal dialysis. Acta Med Scand 220: 47. Matz R: Hyponatremia: Evaluating the correction factor for hyper-
glycemia. Am J Med 108:180–181, 2000143–151, 1986
31. Fernstrom A, Hylander B, Moritz A, et al: Increase of intra- 48. Hillier TA, Abbott RD, Barrett EJ: Hyponatremia: Evaluating
the correction factor for hyperglycemia. Am J Med 106:399–403, 1999abdominal fat in patients treated with continuous ambulatory peri-
toneal dialysis. Perit Dial Int 18:166–171, 1998 49. Strand CL, Garcia H, Costales F: Hyponatremia in spontaneous
hyperglycemia: Correlation studies in 100 patients. Clin Chem32. Woodrow G, Oldroyd B, Stables G, et al: Effects of icodextrin in
automated peritoneal dialysis on blood pressure and bioelectrical 33:1941–1942, 1987
50. Campbell HT, Fincher ME, Sklar AH: Severe hyponatremiaimpedance analysis. Nephrol Dial Transplant 15:862–866, 2000
33. Oda H, Keane WF: Lipid abnormalities in end stage renal disease. without severe hypoosmolality following transurethral resection
of the prostate (TURP) in end-stage renal disease. Am J KidneyNephrol Dial Transplant 13(Suppl 1):45–49, 1998
34. Wheeler DC: Abnormalities of lipoprotein metabolism in CAPD Dis 12:152–155, 1988
51. Palevsky PM, Rendulic D, Diven WF: Maltose-induced hypona-patients. Kidney Int 54(Suppl 56):S41–S46, 1996
35. Little J, Phillips L, Russell L, et al: Longitudinal lipid profiles tremia. Ann Intern Med 118:526–528, 1993
52. Kim S-H, Goto M, Akaike T: Specific binding of glucose-deriva-on CAPD: Their relationship to weight gain, comorbidity, and
dialysis factors. J Am Soc Nephrol 9:1931–1939, 1998 tized polymers to the asialoglycoprotein receptor of mouse primary
hepatocytes. J Biol Chem 276:35312–35319, 200136. Johansson AC, Samuelsson O, Attman PO, et al: Dyslipidemia
in peritoneal dialysis–relation to dialytic variables. Perit Dial Int 53. Blom E, Ali MM, Mortensen B, Huseby NE: Elimination of
alkaline phosphatases from circulation by the galactose receptor.20:306–314, 2000
37. Sniderman A, Cianflone K, Kwiterovich PO Jr, et al: Hyperapo- Different issoforms are cleared at various rates. Clin Chim Acta
270:125–137, 1998betalipoproteinemia: The major dyslipoproteinemia in patients
with chronic renal failure treated with chronic ambulatory perito- 54. Janssen W, Harff G, Caers M, Schellekens A: Positive interfer-
ence of icodextrin metabolites in some enzymatic glucose methods.neal dialysis. Atherosclerosis 65:257–264, 1987
38. Moberly JB, Attman PO, Samuelsson O, et al: Alterations in Clin Chem 44:2379–2380, 1998
55. Wens R, Taminne M, Devriendt J, et al: A previously undescribedlipoprotein composition in peritoneal dialysis patients. Perit Dial
Int 22:220–228, 2002 side effect of icodextrin: Overestimation of glycemia by glucose
analyzer. Perit Dial Int 18:603–609, 199839. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF: Mecha-
nisms of hepatic very low-density lipoprotein overproduction in 56. Grzegorzewska AE, Antczak-Jedrzejczak D, Mariak I: Poly-
glucose dialysis solution influences serum activity of amylase andinsulin resistance. Trends Cardiovasc Med 11:170–176, 2001
40. Attman PO, Samuelsson OG, Moberly J, et al: Apolipoprotein of lipase differently. Adv Perit Dial 16:113–118, 2000
57. Mistry CD, Gokal R: Single daily overnight (12-h dwell) useB-containing lipoproteins in renal failure: The relation to mode
of dialysis. Kidney Int 55:1536–1542, 1999 of 7.5% glucose polymer (Mw 18700; Mn 7300) 0.35% glucose
solution: A 3-month study. Nephrol Dial Transplant 8:443–447, 199341. O’Neal D, Lee P, Murphy B, Best J: Low-density lipoprotein
particle size distribution in end-stage renal disease treated with 58. Burke RA, Hughes G, Moberly JB: Lack of interference of ico-
dextrin on creatinine measurements. Adv Perit Dial 15:234–237,hemodialysis or peritoneal dialysis. Am J Kidney Dis 27:84–91, 1996
42. Bredie SJH, Bosch FH, Demacker PNM, et al: Effects of perito- 1999
